Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers

Next Previous
Trial Profile

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMGN 151 (Primary)
  • Indications Breast cancer; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors ImmunoGen

Most Recent Events

  • 03 Feb 2025 Planned End Date changed from 26 Feb 2027 to 1 Feb 2027.
  • 03 Feb 2025 Planned primary completion date changed from 26 Feb 2024 to 1 Feb 2027.
  • 10 Jan 2025 Planned primary completion date changed from 30 Dec 2024 to 26 Feb 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top